Structure-based rational design enables efficient discovery of a new selective and potent AKT PROTAC degrader

被引:17
|
作者
Zhu, Cheng-Liang [2 ,4 ,7 ]
Luo, Xiaomin [1 ]
Tian, Tian [3 ]
Rao, Zijian [2 ]
Wang, Hanlin [10 ]
Zhou, Zhesheng [2 ]
Mi, Tian [5 ]
Chen, Danni [2 ]
Xu, Yongjin [9 ]
Wu, Yizhe
Che, Jinxin [3 ]
Zhou, Yubo [1 ,5 ,6 ]
Li, Jia [1 ,5 ,6 ]
Dong, Xiaowu [3 ,7 ,8 ]
机构
[1] Nanjing Univ Chinese Med, Sch Chinese Mat Med, Nanjing 210023, Peoples R China
[2] Zhejiang Univ, Inst Pharmacol & Toxicol, Coll Pharmaceut Sci, Zhejiang Prov Key Lab Anticanc Drug Res, Hangzhou 310058, Peoples R China
[3] Zhejiang Univ, Hangzhou Inst Innovat Med, Inst Drug Discovery & Design, Coll Pharmaceut Sci, Hangzhou 310058, Peoples R China
[4] Ctr Drug Safety Evaluat & Res ZJU, Hangzhou 310058, Peoples R China
[5] Chinese Acad Sci, Shanghai Inst Mat Med, Natl Ctr Drug Screening, State Key Lab Drug Res, Shanghai 201203, Peoples R China
[6] Chinese Acad Sci, Zhongshan Inst Drug Discovery, Shanghai Inst Mat Med, Zhongshan Tsuihang New Di 528400, Guangdon, Peoples R China
[7] Zhejiang Univ, Innovat Inst Artificial Intelligence Med, Hangzhou 310016, Peoples R China
[8] Zhejiang Univ, Canc Ctr, Hangzhou 310058, Peoples R China
[9] Canc Hosp Univ Chinese Acad Sci, Chinese Acad Sci, Zhejiang Canc Hosp, Inst Basic Med & Canc, Hangzhou 310005, Peoples R China
[10] Fudan Univ, Sch Pharm, Shanghai 200032, Peoples R China
基金
中国国家自然科学基金;
关键词
AKT; Protein kinase B; PROTAC; Chemical degrader; Rational design; MANTLE CELL LYMPHOMA; BIOLOGICAL EVALUATION; PATHWAY; DEGRADATION; INHIBITION; DERIVATIVES; BTK; IBRUTINIB; MK-2206; TARGET;
D O I
10.1016/j.ejmech.2022.114459
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
AKT and associated signaling pathways have been recognized as promising therapeutic targets for decades, and growing evidence indicates that inhibition or degradation of cellular AKT are viable strategies to treat cancer. Guided by an in silico modeling approach for rational linker design and based on our previous work in this field, we herein efficiently synthesized a small group of cereblon-recruiting AKT PROTAC molecules and identified a highly potent AKT degrader B4. Compared to the existing AKT degraders, B4 has a structurally unique AKT targeting warhead derived from the pyrazole-furan conjugated piperidine derivatives. It induces selective degradation of all three isoforms of AKT and exhibits efficacious anti-proliferation against several human hematological cancers. Notably, B4 demonstrates potent inhibition of AKT downstream signaling superior to its parental inhibitor. Together with its active analogs, B4 expands the arsenal of AKT chemical degraders as a valuable probe to uncover AKTs new functions and as a potential drug candidate to treat cancer.
引用
收藏
页数:15
相关论文
共 50 条
  • [31] Structure-based discovery of potent inhibitors of Axl: design, synthesis, and biological evaluation
    Wu, Shuang
    Liao, Min
    Li, Minxiong
    Sun, Mingming
    Xi, Ning
    Zeng, Youlin
    RSC MEDICINAL CHEMISTRY, 2022, 13 (10): : 1246 - 1264
  • [32] Structure-Based Discovery of Selective Histone Deacetylase 8 Degraders with Potent Anticancer Activity
    Huang, Jinbo
    Zhang, Jun
    Xu, Wenchao
    Wu, Qiong
    Zeng, Rongsheng
    Liu, Zhichao
    Tao, Wenhui
    Chen, Qian
    Wang, Yongqing
    Zhu, Wei-Guo
    JOURNAL OF MEDICINAL CHEMISTRY, 2022, 66 (02) : 1186 - 1209
  • [33] Discovery of a potent Gilteritinib-based FLT3-PROTAC degrader for the treatment of Acute myeloid leukemia
    Ye, Lei
    Cui, Zhenzhen
    Sun, Yu
    Zhou, Haikun
    Rong, Quanjin
    Wang, Dan
    Jin, Jiaming
    Zhang, Qijian
    Kang, Di
    Hu, Lihong
    Wang, Junwei
    BIOORGANIC CHEMISTRY, 2024, 149
  • [34] Structure-guided discovery of novel potent and efficacious proteolysis targeting chimera (PROTAC) degrader of BRD4
    Xiang, Wang
    Wang, Qiwei
    Ran, Kai
    Ren, Jing
    Shi, Yaojie
    Yu, Luoting
    BIOORGANIC CHEMISTRY, 2021, 115
  • [35] Structure-based design and discovery of potent and selective lysine-specific demethylase 1 (LSD1) inhibitors
    Nie, Zhe
    Shi, Lihong
    Lai, Chon
    Severin, Christophe
    Xu, Jiangchun
    Del Rosario, Joselyn R.
    Stansfield, Ryan K.
    Cho, Robert W.
    Kanouni, Toufike
    Veal, James M.
    Stafford, Jeffrey A.
    Chen, Young K.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2019, 29 (01) : 103 - 106
  • [36] Discovery of potent and selective biaryl derivatives as tissue factor/factor VIIa inhibitors through structure-based drug design
    Chand, P
    Kotian, PL
    Dehghani, A
    El-Kattan, Y
    Lin, TH
    Wu, MW
    Rowland, RS
    Raman, K
    Bantia, S
    Arnold, S
    Babu, YS
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2005, 229 : U153 - U154
  • [37] Structure-based design of selective and potent inhibitors of protein-tyrosine phosphatase β
    Lund, IK
    Andersen, HS
    Iversen, LF
    Olsen, OH
    Moller, KB
    Pedersen, AK
    Ge, Y
    Holsworth, DD
    Newman, MJ
    Axe, FU
    Moller, NPH
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (23) : 24226 - 24235
  • [38] Structure-based design of potent and selective tankyrase inhibitors to target the Wnt pathway
    Chakka, Nagasree
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2014, 248
  • [39] Structure-Based Design and Synthesis of Potent and Selective Matrix Metalloproteinase 13 Inhibitors
    Choi, Jun Yong
    Fuerst, Rita
    Knapinska, Anna M.
    Taylor, Alexander B.
    Smith, Lyndsay
    Cao, Xiaohang
    Hart, P. John
    Fields, Gregg B.
    Roush, William R.
    JOURNAL OF MEDICINAL CHEMISTRY, 2017, 60 (13) : 5816 - 5825
  • [40] Structure-based design of potent CDK4 selective inhibitor.
    Honma, T
    Hayashi, K
    Kawanishi, N
    Yoshizumi, T
    Hashimoto, N
    Sugimoto, T
    Nakamura, K
    Takaki, T
    Machida, T
    Fukasawa, K
    Hirai, H
    Iwama, T
    Ikeura, C
    Ikuta, M
    Kamata, K
    Suzuki-Takahashi, I
    Hayama, T
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2001, 221 : U24 - U24